立体定向体部放疗再照射挽救局部复发前列腺癌:去势敏感性的影响
本研究回顾性分析30例局部复发前列腺癌患者接受前列腺再照射(SBRT)的疗效与安全性,中位随访28个月。去势敏感患者3年无复发生存率79%,去势抵抗患者仅9%(p<0.001),且去势抵抗患者失败率和转移率显著更高。去势敏感表型早期接受挽救SBRT可获得良好3年疾病控制和可接受的毒性。
要点
- 去势抵抗患者再照射后失败率91%,显著高于去势敏感患者的32%(p=0.008)。
- 去势敏感患者3年无复发生存79%,去势抵抗患者9%(p<0.001)。
- 急性II级和III级泌尿生殖毒性分别为27%和3%,无≥II级急性胃肠道毒性。
核心结论
- 去势敏感表型的局部复发前列腺癌患者早期接受挽救性SBRT再照射可获得优异的3年疾病控制和可接受的毒性。
- 去势抵抗患者从局部挽救治疗中获益较少。
研究设计与样本
- 前瞻性临床数据库回顾性提取30例连续接受前列腺再照射的患者。
- 所有患者在前列腺特异性抗原失败后行镓PSMA配体PET,18例(60%)获取活检。
- 中位处方剂量为5次6.5 Gy(范围6-8 Gy)。
主要发现
- 中位随访28个月,去势抵抗患者11例中10例失败(91%),去势敏感患者19例中6例失败(32%),p=0.008。
- 去势抵抗患者转移发生率64%(n=7),去势敏感患者16%(n=3),p=0.007。
- 局部控制率为93%,仅2例发生野内局部复发。
- 去势敏感患者2年和3年无复发生存率分别为84%和79%,去势抵抗患者分别为18%和9%,p<0.001。
- 去势敏感患者3年无转移生存率为90%,去势抵抗患者为27%,p<0.01。
关键数值与推荐
- 急性II级和III级泌尿生殖毒性发生率分别为27%和3%,晚期分别为30%和3%。
- 无≥II级急性胃肠道毒性,仅1例(3%)发生晚期II级毒性。
临床怎么用
- 对去势敏感表型的局部复发前列腺癌可考虑早期行挽救性SBRT再照射。
- PSMA显像用于检测局部复发以及使用直肠保护装置的精准放疗应作为放射性复发前列腺癌的新挽救策略进一步研究。
局限性
- 回顾性研究,样本量较小(30例)。
- 随访时间较短(中位28个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advances in imaging, biomaterials and precision radiotherapy provide new opportunities to salvage locally recurrent prostate cancer (PC). This study evaluates the efficacy and safety of re-irradiation using stereotactic body radiation therapy (SBRT). We hypothesized that patients with castrate-resistant PC (CRPC) would benefit less from local salvage. METHODS: A prospective clinical database was reviewed to extract 30 consecutive patients treated with prostate re-irradiation. Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography was performed following prostate-specific antigen failure in all patients and biopsy was obtained in 18 patients (60%). Re-irradiation was either focal (n = 13) or whole-gland (n = 17). Endo-rectal balloons were used in twenty-two patients and hydrogel spacers in eight patients. The median prescription dose was 5 fractions of 6.5 (range: 6-8) Gray (Gy). RESULTS: Median follow-up was 28 months. Failure occurred in 10 (out of 11) CRPC patients versus 6 (out of 19) castrate-sensitive patients (91% vs. 32%, p = 0.008) after a median of 13 and 23 months, respectively. Metastases occurred in 64% (n = 7) of CRPC patients versus 16% (n = 3) of castrate-sensitive patients (p = 0.007). Two patients experienced local in-field recurrence, thus local control was 93%. The 2 and 3-year recurrence-free survival were 84% and 79% for castrate-sensitive patients versus 18% and 9% for CRPC patients (p < 0.001), and 3-year metastasis-free survival was 90% versus 27% (p < 0.01) for castrate-sensitive and CRPC patients, respectively. Acute grade II and III genitourinary (GU) toxicity occurred in 27% and 3%, and late GU toxicity in 30% and 3%, respectively. No ≥ grade II acute gastrointestinal (GI) toxicity occurred, and only one patient (3%) developed late grade II toxicity. CONCLUSIONS: Early delivery of salvage SBRT for local recurrence is associated with excellent 3-year disease control and acceptable toxicity in the castrate-sensitive phenotype. PSMA imaging for detection of local recurrence and the use of precision radiotherapy with rectal protective devices should be further investigated as a novel salvage strategy for radio-recurrent PC.
引用
- Lewin R, Amit U, Laufer M, et al. Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes. Radiat Oncol. 2021. PMID: 34162398. doi:10.1186/s13014-021-01839-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。